Why Is Pacira BioSciences (PCRX) Stock Up +43.93% Today?
Key Takeaways
- PCRX surged roughly 43.93% on news of an all-cash acquisition offer.
- Primary catalyst: Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing the equity at about $1.65 billion.
- The deal price represents a substantial premium over the prior session's closing level and the stock's 52-week high.
- The move was company-specific, diverging sharply from a broadly softer tape across major indices.
- Traders are now watching tender-offer progress and the expected closing by the end of 2026.
Opening Summary
Pacira BioSciences, Inc. (PCRX), a biopharmaceutical company focused on innovative non-opioid pain therapies, saw its shares rocket higher on Thursday after VTRS (Viatris Inc.) announced a definitive agreement to acquire the company. The stock climbed to roughly $36.27, up from a prior close of $25.20 — a gain of about 43.93%, or $11.07 per share. The move was driven overwhelmingly by a single, clear catalyst: a $1.65 billion all-cash takeover bid of $36.50 per share.
M&A Catalyst: Viatris' $36.50-Per-Share Cash Offer
The dominant driver behind today's move is the announced acquisition. Viatris, a global pharmaceutical company, agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, in a transaction valued at roughly $1.65 billion on an equity basis. The deal price sits well above the stock's recent trading range and above its prior 52-week high, explaining the magnitude of the market reaction.
Strategically, the acquisition adds two established, high-margin, patent-protected commercial products to Viatris' portfolio: EXPAREL, a long-acting local analgesic used for acute postsurgical pain, and ZILRETTA, an extended-release injectable for osteoarthritis knee pain. Viatris said the combination is expected to position it as a leader in non-opioid pain management and to be immediately accretive to its financial guidance metrics. The company plans to fund the deal primarily from excess cash, with the remainder from short-term borrowings.
Secondary Drivers: Analyst Support and a European Distribution Deal
While the takeover bid is the headline catalyst, a handful of supportive developments helped frame the narrative ahead of the announcement. Truist Securities had recently raised its price target on Pacira BioSciences to $31 from $30 while maintaining a buy rating, signaling confidence in the company's valuation and growth outlook. Separately, Pacira struck an exclusive agreement with Italy-based Molteni Farmaceutici to commercialize EXPAREL across select European markets, adding an upfront payment, supply revenue, and potential royalties while Pacira retains manufacturing control. These factors underscored an "undervalued" narrative that made the company an attractive acquisition target.
Market Context and Trading Activity
The surge in PCRX was a company-specific, deal-driven event rather than a reflection of broader market strength. On a day when major benchmarks were trading modestly lower, the stock's sharp advance stood in stark contrast, confirming that the acquisition announcement — not sector or macro momentum — was the primary force. The transaction carries a meaningful control premium, with the offer price eclipsing the stock's prior 52-week high and effectively resetting expectations around the company's standalone valuation. Trading activity concentrated heavily around the deal price, a typical pattern for all-cash mergers where arbitrage and tender-offer mechanics dominate price discovery.
What Comes Next for PCRX
Looking ahead, the path for PCRX is now largely defined by the mechanics of the acquisition rather than standalone fundamentals. Viatris intends to commence a tender offer for all outstanding shares, with completion conditioned on customary items including the tender of a majority of Pacira's outstanding shares and the expiration or termination of regulatory waiting periods. The transaction is expected to close by the end of 2026, after which Pacira would become a wholly owned subsidiary of Viatris and its common stock would cease trading on the Nasdaq Global Select Market. Key risks include the potential for a superior competing offer, the $62 million termination fee structure, and the possibility of delays in closing. For investors, the primary considerations now center on deal completion certainty and the gap between the current trading price and the $36.50 offer price.
Trending AI Robots
For traders seeking a data-driven edge across the market, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing AI trading bots. Tickeron provides hundreds of AI-powered trading bots covering thousands of tickers, but only those delivering standout results under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols. Explore the Trending AI Robots to see which automated strategies are currently leading the field.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
PCRX in -1.79% downward trend, sliding for three consecutive days on October 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PCRX declined for three days, in 228 of 303 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 57 cases where PCRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on PCRX as a result. In 60 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for PCRX just turned positive on October 07, 2026. Looking at past instances where PCRX's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
PCRX moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCRX crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +2.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in 219 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
PCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 136 of 189 cases where PCRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.506) is normal, around the industry mean (43.873). P/E Ratio (72.543) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.684) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.416) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of injectable therapeutic products
Industry PharmaceuticalsGeneric
Advertisement